MEI Pharma To Host Analyst And Investor Day

                 MEI Pharma To Host Analyst And Investor Day

Live Webcast from New York on Wednesday, December 11th

PR Newswire

SAN DIEGO, Dec. 5, 2013

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, will host an Analyst and Investor Day on Thursday, December 11, 2013
from 12:00 noon to 2:00 p.m. Eastern time in New York City. The event will
feature updates by Daniel P. Gold, Ph.D., President and Chief Executive
Officer, and Robert D. Mass, MD, Chief Medical Officer, on the Company's
clinical development programs for its lead oncology drug candidates,
Pracinostat and ME-344, along with presentations by Dr. Guillermo
Garcia-Manero of the MD Anderson Cancer Center and Dr. Jeffrey R. Infante of
the Sarah Cannon Research Institute and Tennessee Oncology. A live webcast of
the event will be accessible at A replay will be
available approximately one hour after its conclusion.


About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
being developed for advanced hematologic diseases, such as myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). The Company initiated a
randomized, placebo-controlled Phase II trial of Pracinostat in combination
with Vidaza (azacitidine) in patients with previously untreated MDS in June
2013. An open-label Phase II trial of Pracinostat in combination with Vidaza
in elderly patients with AML who are unsuitable for intensive chemotherapy is
open for enrollment. MEI Pharma is also developing ME-344, a mitochondrial
inhibitor derived from its isoflavone-based technology platform. Results from
a first-in-human, single-agent clinical study of ME-344 in patients with
refractory solid tumors were presented in October 2013. In September 2013, the
Company further expanded its pipeline of drug candidates with the acquisition
of PWT143, a highly selective PI3-kinase delta inhibitor. For more
information, go to

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking

SOURCE MEI Pharma, Inc.

Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, (858) 792-3729,